After initial results over 5 years ago, long-term follow-up data from 3 clinical trials – CheckMate 067, COLUMBUS, and ABC – show a durable and sustained clinical benefit for patients with melanoma. In the phase 3 CheckMate 067...
Read MoreFirst-line treatment of patients with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) with pembrolizumab improves overall survival, but the prespecified threshold for...
Read MoreFirst results of the phase 3 KEYNOTE 564 trial show that adjuvant therapy with pembrolizumab after nephrectomy enhances disease-free survival of patients treated for locoregional clear cell renal cell cancer (RCC). Nephrectomy...
Read MoreResults of the randomized, phase 3 OUTBACK trial do not support the use of adjuvant chemotherapy after chemoradiation in women with locally advanced cervical cancer. At 5 years, both overall and progression-free survival were...
Read MoreA first interim analysis of the OlympiA trial demonstrates significantly improved invasive disease-free survival in patients with high risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer after 1 year of adjuvant...
Read MoreAddition of the BCL2 inhibitor venetoclax to endocrine therapy does not improve clinical benefit in patients with ER-positive, HER2-negative, locally advanced/metastatic breast cancer, according to the primary analysis of the...
Read MoreFirst results of the randomized, phase 3 CheckMate 648 study demonstrate superior overall survival of first-line treatment with nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone. Standard...
Read MoreA 2-year update of the CheckMate 9LA trial shows sustained benefit of first-line treatment with nivolumab plus ipilimumab plus 2 cycles of chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung...
Read MoreAddition of 177Lu-PSMA-617 therapy to standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC) significantly improves survival, according to results from the randomized, phase 3 VISION trial....
Read MoreRBN-2397 is a potent, selective inhibitor of PARP7 that could potentially release the brake on the antitumor immunity, is well tolerated, and demonstrated proof of mechanism in a first-in-human trial. Targeting cytosolic nucleic...
Read MoreFirst results of the GAIN/iCAT2 Consortium trial show the importance of molecular profiling of solid tumors in young patients. Next generation sequencing (NGS) assays are now a standard part of clinical care for many adult solid...
Read More
Are you caught up on trials on multiple sclerosis that have been released from AAN 2021? Test your...
Read More
Electronic monitoring of Covid-19 symptoms wins high marks from patients In the 1980s the...
Read More
Good anti-tumor activity and manageable safety profile seen When added to concurrent...
Read More
Confirmed response seen in patients who relapse after osimertinib Patients with non-small cell...
Read More
Objective response observed at 1.4 months Targeted therapies have greatly improved outcomes in...
Read More
Survival benefit seen in early-stage HER-2 negative breast cancer with BRCA1/2 mutations Adding 12...
Read MoreSignificant improvements in mortality among non-small cell lung cancer (NSCLC) cancer patients have been reported over the past 2 decades, according to Surveillance, Epidemiology, and End Results Program (SEER) data. The timing...
Read MoreLiquid biopsies based on circulating tumor DNA (ctDNA) analysis are being investigated for detection of residual disease and recurrence in patients with early-stage non-small cell lung cancer (NSCLC). Due to low ctDNA levels in...
Read MoreHerpes zoster (HZ) is prevalent in patients with Chronic Lymphocytic Leukemia (CLL) and affects younger patients who require chemotherapy. The risk of developing HZ increases in recipients of first and second line chemotherapy....
Read More
